메뉴 건너뛰기




Volumn 6, Issue NOV, 2016, Pages

Recent advances in immunotherapy in metastatic NSCLC

Author keywords

Cancer immunotherapy; CTLA4; NSCLC; PD1; PDL1

Indexed keywords

AFATINIB; ATEZOLIZUMAB; AVELUMAB; BAVITUXIMAB; CHECKPOINT KINASE INHIBITOR; CRIZOTINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; DURVALUMAB; ERLOTINIB; IMMUNOMODULATING AGENT; INDOLEAMINE 2,3 DIOXYGENASE; IPILIMUMAB; KIDNEY INJURY MOLECULE 1; LAG 525; NIVOLUMAB; PEMBROLIZUMAB; PLATINUM; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; UNCLASSIFIED DRUG; URELUMAB;

EID: 85006355534     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00239     Document Type: Short Survey
Times cited : (31)

References (66)
  • 1
    • 84960949820 scopus 로고
    • Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications
    • Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J (1957) 1(5023):841-7. doi:10.1136/bmj.1.5023.841
    • (1957) Br Med J , vol.1 , Issue.5023 , pp. 841-847
    • Burnet, M.1
  • 2
    • 84864214537 scopus 로고    scopus 로고
    • Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC
    • Zhuang X, Zhang X, Xia X, Zhang C, Liang X, Gao L, et al. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol (2012) 137(6):978-85. doi:10.1309/AJCP9Q6OVLVSHTMY
    • (2012) Am J Clin Pathol , vol.137 , Issue.6 , pp. 978-985
    • Zhuang, X.1    Zhang, X.2    Xia, X.3    Zhang, C.4    Liang, X.5    Gao, L.6
  • 3
    • 4344671644 scopus 로고    scopus 로고
    • Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance
    • Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Liénard D, Lejeune F, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 64(8):2865-73. doi:10.1158/0008-5472.CAN-03-3066
    • (2004) Cancer Res , vol.64 , Issue.8 , pp. 2865-2873
    • Zippelius, A.1    Batard, P.2    Rubio-Godoy, V.3    Bioley, G.4    Liénard, D.5    Lejeune, F.6
  • 4
    • 0032416085 scopus 로고    scopus 로고
    • Viral immune evasion due to persistence of activated T cells without effector function
    • Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med (1998) 188(12):2205-13. doi:10.1084/jem.188.12.2205
    • (1998) J Exp Med , vol.188 , Issue.12 , pp. 2205-2213
    • Zajac, A.J.1    Blattman, J.N.2    Murali-Krishna, K.3    Sourdive, D.J.4    Suresh, M.5    Altman, J.D.6
  • 5
    • 35349014587 scopus 로고    scopus 로고
    • Molecular signature of CD8+ T cell exhaustion during chronic viral infection
    • Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity (2007) 27(4):670-84. doi:10.1016/j.immuni.2007.09.006
    • (2007) Immunity , vol.27 , Issue.4 , pp. 670-684
    • Wherry, E.J.1    Ha, S.J.2    Kaech, S.M.3    Haining, W.N.4    Sarkar, S.5    Kalia, V.6
  • 6
    • 84937837169 scopus 로고    scopus 로고
    • Molecular and cellular insights into T cell exhaustion
    • Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol (2015) 15(8):486-99. doi:10.1038/nri3862
    • (2015) Nat Rev Immunol , vol.15 , Issue.8 , pp. 486-499
    • Wherry, E.J.1    Kurachi, M.2
  • 7
    • 0033024863 scopus 로고    scopus 로고
    • High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993
    • Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 17(7):2105-16.
    • (1999) J Clin Oncol , vol.17 , Issue.7 , pp. 2105-2116
    • Atkins, M.B.1    Lotze, M.T.2    Dutcher, J.P.3    Fisher, R.I.4    Weiss, G.5    Margolin, K.6
  • 8
    • 0033848628 scopus 로고    scopus 로고
    • High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update
    • Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 6(Suppl 1):S11-4.
    • (2000) Cancer J Sci Am , vol.6 , pp. S11-S14
    • Atkins, M.B.1    Kunkel, L.2    Sznol, M.3    Rosenberg, S.A.4
  • 11
    • 0018118221 scopus 로고
    • Long-term results in combined-modality treatment of small cell carcinoma of the lung
    • Einhorn LH, Bond WH, Hornback N, Joe BT. Long-term results in combined-modality treatment of small cell carcinoma of the lung. Semin Oncol (1978) 5(3):309-13.
    • (1978) Semin Oncol , vol.5 , Issue.3 , pp. 309-313
    • Einhorn, L.H.1    Bond, W.H.2    Hornback, N.3    Joe, B.T.4
  • 12
    • 0026653868 scopus 로고
    • Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer
    • Jansen RL, Slingerland R, Goey SH, Franks CR, Bolhuis RL, Stoter G. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother (1992) 12(1):70-3. doi:10.1097/00002371-199207000-00009
    • (1992) J Immunother , vol.12 , Issue.1 , pp. 70-73
    • Jansen, R.L.1    Slingerland, R.2    Goey, S.H.3    Franks, C.R.4    Bolhuis, R.L.5    Stoter, G.6
  • 14
    • 84936749833 scopus 로고    scopus 로고
    • Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer
    • Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol (2015) 33(18):2004-12. doi:10.1200/JCO.2014.58.3708
    • (2015) J Clin Oncol , vol.33 , Issue.18 , pp. 2004-2012
    • Gettinger, S.N.1    Horn, L.2    Gandhi, L.3    Spigel, D.R.4    Antonia, S.J.5    Rizvi, N.A.6
  • 15
  • 16
    • 84944937210 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
    • Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med (2015) 373(17):1627-39. doi:10.1056/NEJMoa1507643
    • (2015) N Engl J Med , vol.373 , Issue.17 , pp. 1627-1639
    • Borghaei, H.1    Paz-Ares, L.2    Horn, L.3    Spigel, D.R.4    Steins, M.5    Ready, N.E.6
  • 17
    • 84950117835 scopus 로고    scopus 로고
    • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
    • 10027
    • Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2016) 387(10027):1540-50. doi:10.1016/S0140-6736(15)01281-7
    • (2016) Lancet , vol.387 , pp. 1540-1550
    • Herbst, R.S.1    Baas, P.2    Kim, D.W.3    Felip, E.4    Pérez-Gracia, J.L.5    Han, J.Y.6
  • 18
    • 0032736029 scopus 로고    scopus 로고
    • B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
    • Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 5(12):1365-9. doi:10.1038/70932
    • (1999) Nat Med , vol.5 , Issue.12 , pp. 1365-1369
    • Dong, H.1    Zhu, G.2    Tamada, K.3    Chen, L.4
  • 20
    • 0034596948 scopus 로고    scopus 로고
    • Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
    • Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 192(7):1027-34. doi:10.1084/jem.192.7.1027
    • (2000) J Exp Med , vol.192 , Issue.7 , pp. 1027-1034
    • Freeman, G.J.1    Long, A.J.2    Iwai, Y.3    Bourque, K.4    Chernova, T.5    Nishimura, H.6
  • 21
    • 84962038946 scopus 로고    scopus 로고
    • Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
    • 10030
    • Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet (2016) 387(10030):1837-46. doi:10.1016/S0140-6736(16)00587-0
    • (2016) Lancet , vol.387 , pp. 1837-1846
    • Fehrenbacher, L.1    Spira, A.2    Ballinger, M.3    Kowanetz, M.4    Vansteenkiste, J.5    Mazieres, J.6
  • 22
    • 85009840975 scopus 로고    scopus 로고
    • 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)
    • Besse B, Johnson M, Janne PA, Garassino M, Eberhardt WEE, Peter S, et al. 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Eur J Cancer (2015) 51:S717-8. doi:10.1016/S0959-8049(16)31938-4
    • (2015) Eur J Cancer , vol.51 , pp. S717-S718
    • Besse, B.1    Johnson, M.2    Janne, P.A.3    Garassino, M.4    Eberhardt, W.E.E.5    Peter, S.6
  • 23
    • 84944734156 scopus 로고    scopus 로고
    • Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)
    • Rizvi NA. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol (2015) 33(S1):8032.
    • (2015) J Clin Oncol , vol.33 , pp. 8032
    • Rizvi, N.A.1
  • 24
    • 85006393710 scopus 로고    scopus 로고
    • Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non-small-cell lung cancer
    • Antonia S. Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non-small-cell lung cancer. J Clin Oncol (2016) 34(15_suppl):9029.
    • (2016) J Clin Oncol , vol.34 , Issue.15 , pp. 9029
    • Antonia, S.1
  • 25
    • 84944751040 scopus 로고    scopus 로고
    • Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy
    • Gulley JL, Spigel D, Kelly K, Chandler JC, Rajan A, Hassan R, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. J Clin Oncol (2015) 33(15_suppl):8034.
    • (2015) J Clin Oncol , vol.33 , Issue.15 , pp. 8034
    • Gulley, J.L.1    Spigel, D.2    Kelly, K.3    Chandler, J.C.4    Rajan, A.5    Hassan, R.6
  • 26
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    • Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 26(21):3543-51. doi:10.1200/JCO.2007.15.0375
    • (2008) J Clin Oncol , vol.26 , Issue.21 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    von Pawel, J.3    Biesma, B.4    Vansteenkiste, J.5    Manegold, C.6
  • 27
    • 84859128199 scopus 로고    scopus 로고
    • Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
    • Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 4(127):127ra137. doi:10.1126/scitranslmed.3003689
    • (2012) Sci Transl Med , vol.4 , Issue.127
    • Taube, J.M.1    Anders, R.A.2    Young, G.D.3    Xu, H.4    Sharma, R.5    McMiller, T.L.6
  • 28
    • 84962129035 scopus 로고    scopus 로고
    • Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors
    • Thommen DS, Schreiner J, Müller P, Herzig P, Roller A, Belousov A, et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res (2015) 3(12):1344-55. doi:10.1158/2326-6066.CIR-15-0097
    • (2015) Cancer Immunol Res , vol.3 , Issue.12 , pp. 1344-1355
    • Thommen, D.S.1    Schreiner, J.2    Müller, P.3    Herzig, P.4    Roller, A.5    Belousov, A.6
  • 29
    • 84928761118 scopus 로고    scopus 로고
    • Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
    • Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 348(6230):124-8. doi:10.1126/science.aaa1348
    • (2015) Science , vol.348 , Issue.6230 , pp. 124-128
    • Rizvi, N.A.1    Hellmann, M.D.2    Snyder, A.3    Kvistborg, P.4    Makarov, V.5    Havel, J.J.6
  • 30
    • 84966309581 scopus 로고    scopus 로고
    • Cancer immunology. The "cancer immunogram"
    • Blank CU, Haanen JB, Ribas A, Schumacher TN. Cancer immunology. The "cancer immunogram". Science (2016) 352(6286):658-60. doi:10.1126/science.aaf2834
    • (2016) Science , vol.352 , Issue.6286 , pp. 658-660
    • Blank, C.U.1    Haanen, J.B.2    Ribas, A.3    Schumacher, T.N.4
  • 31
    • 78449258549 scopus 로고    scopus 로고
    • Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy
    • Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol (2010) 37(5):533-46. doi:10.1053/j.seminoncol.2010.09.015
    • (2010) Semin Oncol , vol.37 , Issue.5 , pp. 533-546
    • Hoos, A.1    Ibrahim, R.2    Korman, A.3    Abdallah, K.4    Berman, D.5    Shahabi, V.6
  • 32
    • 84863113633 scopus 로고    scopus 로고
    • Immunotherapies for non-small-cell lung cancer and mesothelioma
    • Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol (2012) 13(7):e301-10. doi:10.1016/S1470-2045(12)70126-2
    • (2012) Lancet Oncol , vol.13 , Issue.7 , pp. e301-e310
    • Thomas, A.1    Hassan, R.2
  • 33
    • 84863911486 scopus 로고    scopus 로고
    • Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study
    • Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 30(17):2046-54. doi:10.1200/JCO.2011.38.4032
    • (2012) J Clin Oncol , vol.30 , Issue.17 , pp. 2046-2054
    • Lynch, T.J.1    Bondarenko, I.2    Luft, A.3    Serwatowski, P.4    Barlesi, F.5    Chacko, R.6
  • 34
    • 84881086323 scopus 로고    scopus 로고
    • Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host
    • Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer (2013) 13(7):497-510. doi:10.1038/nrc3486
    • (2013) Nat Rev Cancer , vol.13 , Issue.7 , pp. 497-510
    • Timp, W.1    Feinberg, A.P.2
  • 35
    • 77954122580 scopus 로고    scopus 로고
    • Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors
    • Cowan LA, Talwar S, Yang AS. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics (2010) 2(1):71-86. doi:10.2217/epi.09.44
    • (2010) Epigenomics , vol.2 , Issue.1 , pp. 71-86
    • Cowan, L.A.1    Talwar, S.2    Yang, A.S.3
  • 36
    • 84946222432 scopus 로고    scopus 로고
    • Aberrant epigenetic regulation: a central contributor to lung carcinogenesis and a new therapeutic target
    • Juergens RA, Rudin CM. Aberrant epigenetic regulation: a central contributor to lung carcinogenesis and a new therapeutic target. Am Soc Clin Oncol Educ Book (2013) 2013:295-300. doi:10.1200/EdBook_AM.2013.33.e295
    • (2013) Am Soc Clin Oncol Educ Book , vol.2013 , pp. 295-300
    • Juergens, R.A.1    Rudin, C.M.2
  • 37
    • 84655163371 scopus 로고    scopus 로고
    • Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer
    • Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 1(7):598-607. doi:10.1158/2159-8290.CD-11-0214
    • (2011) Cancer Discov , vol.1 , Issue.7 , pp. 598-607
    • Juergens, R.A.1    Wrangle, J.2    Vendetti, F.P.3    Murphy, S.C.4    Zhao, M.5    Coleman, B.6
  • 38
    • 84940403834 scopus 로고    scopus 로고
    • DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts
    • Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell (2015) 162(5):961-73. doi:10.1016/j.cell.2015.07.056
    • (2015) Cell , vol.162 , Issue.5 , pp. 961-973
    • Roulois, D.1    Loo Yau, H.2    Singhania, R.3    Wang, Y.4    Danesh, A.5    Shen, S.Y.6
  • 39
    • 84961226039 scopus 로고    scopus 로고
    • Immunotherapy: PD-1 says goodbye, TIM-3 says hello
    • Romero D. Immunotherapy: PD-1 says goodbye, TIM-3 says hello. Nat Rev Clin Oncol (2016) 13(4):202-3. doi:10.1038/nrclinonc.2016.40
    • (2016) Nat Rev Clin Oncol , vol.13 , Issue.4 , pp. 202-203
    • Romero, D.1
  • 40
    • 84890130945 scopus 로고    scopus 로고
    • Alterations of immune response of non-small cell lung cancer with azacytidine
    • Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget (2013) 4(11):2067-79. doi:10.18632/oncotarget.1542
    • (2013) Oncotarget , vol.4 , Issue.11 , pp. 2067-2079
    • Wrangle, J.1    Wang, W.2    Koch, A.3    Easwaran, H.4    Mohammad, H.P.5    Vendetti, F.6
  • 41
    • 84958555198 scopus 로고    scopus 로고
    • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
    • Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun (2016) 7:10501. doi:10.1038/ncomms10501
    • (2016) Nat Commun , vol.7 , pp. 10501
    • Koyama, S.1    Akbay, E.A.2    Li, Y.Y.3    Herter-Sprie, G.S.4    Buczkowski, K.A.5    Richards, W.G.6
  • 43
    • 78650208859 scopus 로고    scopus 로고
    • The CD4-like molecule LAG-3, biology and therapeutic applications
    • Sierro S, Romero P, Speiser DE. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets (2011) 15(1):91-101. doi:10.1517/14712598.2011.540563
    • (2011) Expert Opin Ther Targets , vol.15 , Issue.1 , pp. 91-101
    • Sierro, S.1    Romero, P.2    Speiser, D.E.3
  • 45
    • 84863115998 scopus 로고    scopus 로고
    • Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape
    • Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2012) 72(4):917-27. doi:10.1158/0008-5472.CAN-11-1620
    • (2012) Cancer Res , vol.72 , Issue.4 , pp. 917-927
    • Woo, S.R.1    Turnis, M.E.2    Goldberg, M.V.3    Bankoti, J.4    Selby, M.5    Nirschl, C.J.6
  • 46
    • 77952343328 scopus 로고    scopus 로고
    • Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
    • Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 107(17):7875-80. doi:10.1073/pnas.1003345107
    • (2010) Proc Natl Acad Sci U S A , vol.107 , Issue.17 , pp. 7875-7880
    • Matsuzaki, J.1    Gnjatic, S.2    Mhawech-Fauceglia, P.3    Beck, A.4    Miller, A.5    Tsuji, T.6
  • 47
    • 80455127305 scopus 로고    scopus 로고
    • Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors
    • Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, et al. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res (2011) 17(21):6888-96. doi:10.1158/1078-0432.CCR-11-1074
    • (2011) Clin Cancer Res , vol.17 , Issue.21 , pp. 6888-6896
    • Gerber, D.E.1    Stopeck, A.T.2    Wong, L.3    Rosen, L.S.4    Thorpe, P.E.5    Shan, J.S.6
  • 48
    • 20144374032 scopus 로고    scopus 로고
    • A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice
    • Huang X, Bennett M, Thorpe PE. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res (2005) 65(10):4408-16. doi:10.1158/0008-5472.CAN-05-0031
    • (2005) Cancer Res , vol.65 , Issue.10 , pp. 4408-4416
    • Huang, X.1    Bennett, M.2    Thorpe, P.E.3
  • 49
    • 4344597636 scopus 로고    scopus 로고
    • Phosphatidylserine regulates the maturation of human dendritic cells
    • Chen X, Doffek K, Sugg SL, Shilyansky J. Phosphatidylserine regulates the maturation of human dendritic cells. J Immunol (2004) 173(5):2985-94. doi:10.4049/jimmunol.173.5.2985
    • (2004) J Immunol , vol.173 , Issue.5 , pp. 2985-2994
    • Chen, X.1    Doffek, K.2    Sugg, S.L.3    Shilyansky, J.4
  • 50
    • 84971617618 scopus 로고    scopus 로고
    • Docetaxel combined with bavituximab in previously treated, advanced nonsquamous non-small-cell lung cancer
    • Gerber DE, Spigel DR, Giorgadze D, Shtivelband M, Ponomarova OV, Shan JS, et al. Docetaxel combined with bavituximab in previously treated, advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer (2016) 17(3):169-76. doi:10.1016/j.cllc.2016.02.003
    • (2016) Clin Lung Cancer , vol.17 , Issue.3 , pp. 169-176
    • Gerber, D.E.1    Spigel, D.R.2    Giorgadze, D.3    Shtivelband, M.4    Ponomarova, O.V.5    Shan, J.S.6
  • 51
    • 0033990826 scopus 로고    scopus 로고
    • Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection
    • Kudo Y, Boyd CA. Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection. Biochim Biophys Acta (2000) 1500(1):119-24. doi:10.1016/S0925-4439(99)00096-4
    • (2000) Biochim Biophys Acta , vol.1500 , Issue.1 , pp. 119-124
    • Kudo, Y.1    Boyd, C.A.2
  • 52
    • 0022354604 scopus 로고
    • Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme
    • Yamazaki F, Kuroiwa T, Takikawa O, Kido R. Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. Biochem J (1985) 230(3):635-8. doi:10.1042/bj2300635
    • (1985) Biochem J , vol.230 , Issue.3 , pp. 635-638
    • Yamazaki, F.1    Kuroiwa, T.2    Takikawa, O.3    Kido, R.4
  • 53
    • 0032555614 scopus 로고    scopus 로고
    • Prevention of allogeneic fetal rejection by tryptophan catabolism
    • Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 281(5380):1191-3. doi:10.1126/science.281.5380.1191
    • (1998) Science , vol.281 , Issue.5380 , pp. 1191-1193
    • Munn, D.H.1    Zhou, M.2    Attwood, J.T.3    Bondarev, I.4    Conway, S.J.5    Marshall, B.6
  • 54
    • 1542374723 scopus 로고    scopus 로고
    • CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase
    • Swanson KA, Zheng Y, Heidler KM, Mizobuchi T, Wilkes DS. CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am J Respir Cell Mol Biol (2004) 30(3):311-8. doi:10.1165/rcmb.2003-0268OC
    • (2004) Am J Respir Cell Mol Biol , vol.30 , Issue.3 , pp. 311-318
    • Swanson, K.A.1    Zheng, Y.2    Heidler, K.M.3    Mizobuchi, T.4    Wilkes, D.S.5
  • 56
    • 84936147067 scopus 로고    scopus 로고
    • Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
    • Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey L, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med (2015) 373(1):23-34. doi:10.1056/NEJMoa1504030
    • (2015) N Engl J Med , vol.373 , Issue.1 , pp. 23-34
    • Larkin, J.1    Chiarion-Sileni, V.2    Gonzalez, R.3    Grob, J.J.4    Cowey, L.5    Lao, C.D.6
  • 57
    • 84984681480 scopus 로고    scopus 로고
    • CheckMate 012: safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC
    • Hellmann MDEA. CheckMate 012: safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. J Clin Oncol (2016) 34(Suppl):abstr 3001.
    • (2016) J Clin Oncol , vol.34
    • Hellmann, M.D.E.A.1
  • 58
    • 0037050352 scopus 로고    scopus 로고
    • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    • Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 346(2):92-8. doi:10.1056/NEJMoa011954
    • (2002) N Engl J Med , vol.346 , Issue.2 , pp. 92-98
    • Schiller, J.H.1    Harrington, D.2    Belani, C.P.3    Langer, C.4    Sandler, A.5    Krook, J.6
  • 59
    • 67650281462 scopus 로고    scopus 로고
    • Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer
    • Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2009) 27(19):3217-24. doi:10.1200/JCO.2008.20.9114
    • (2009) J Clin Oncol , vol.27 , Issue.19 , pp. 3217-3224
    • Grønberg, B.H.1    Bremnes, R.M.2    Fløtten, O.3    Amundsen, T.4    Brunsvig, P.F.5    Hjelde, H.H.6
  • 60
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowalti A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 355(24):2542-50. doi:10.1056/NEJMoa061884
    • (2006) N Engl J Med , vol.355 , Issue.24 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3    Brahmer, J.4    Schiller, J.H.5    Dowalti, A.6
  • 61
    • 84947444749 scopus 로고    scopus 로고
    • Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohorts A and C
    • Papadimitrakopoulou V, Patnaik A, Borghaei H, Stevenson J, Gandhi L, Gubens MA, et al. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohorts A and C. J Clin Oncol (2015) 33(Suppl):abstr 8031.
    • (2015) J Clin Oncol , vol.33
    • Papadimitrakopoulou, V.1    Patnaik, A.2    Borghaei, H.3    Stevenson, J.4    Gandhi, L.5    Gubens, M.A.6
  • 62
    • 85040257501 scopus 로고    scopus 로고
    • 136O: osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial
    • Ahn MJ, Yang J, Yu H, Saka H, Ramalingam S, Goto K, et al. 136O: osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. J Thorac Oncol (2016) 11(4):S115. doi:10.1016/S1556-0864(16)30246-5
    • (2016) J Thorac Oncol , vol.11 , Issue.4 , pp. S115
    • Ahn, M.J.1    Yang, J.2    Yu, H.3    Saka, H.4    Ramalingam, S.5    Goto, K.6
  • 63
    • 84964573640 scopus 로고    scopus 로고
    • Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
    • Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol (2016) 27(4):559-74. doi:10.1093/annonc/mdv623
    • (2016) Ann Oncol , vol.27 , Issue.4 , pp. 559-574
    • Champiat, S.1    Lambotte, O.2    Barreau, E.3    Belkhir, R.4    Berdelou, A.5    Carbonnel, F.6
  • 64
    • 84874605864 scopus 로고    scopus 로고
    • Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
    • Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 31(5):616-22. doi:10.1200/JCO.2012.44.6112
    • (2013) J Clin Oncol , vol.31 , Issue.5 , pp. 616-622
    • Ribas, A.1    Kefford, R.2    Marshall, M.A.3    Punt, C.J.4    Haanen, J.B.5    Marmol, M.6
  • 65
    • 84931083080 scopus 로고    scopus 로고
    • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
    • Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 16(4):375-84. doi:10.1016/S1470-2045(15)70076-8
    • (2015) Lancet Oncol , vol.16 , Issue.4 , pp. 375-384
    • Weber, J.S.1    D'Angelo, S.P.2    Minor, D.3    Hodi, F.S.4    Gutzmer, R.5    Neyns, B.6
  • 66
    • 84983652291 scopus 로고    scopus 로고
    • Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer
    • Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol (2016) 34(25):2980-7. doi:10.1200/jco.2016.66.9929
    • (2016) J Clin Oncol , vol.34 , Issue.25 , pp. 2980-2987
    • Gettinger, S.1    Rizvi, N.A.2    Chow, L.Q.3    Borghaei, H.4    Brahmer, J.5    Ready, N.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.